EGFL7 promotes immune evasion in glioblastoma by interaction with integrin β2

This study demonstrates that EGFL7 promotes immune evasion in glioblastoma by interacting with integrin β2 to drive T cell exhaustion and macrophage polarization, revealing that targeting this axis enhances the efficacy of anti-PD1 immunotherapy and extends survival in mouse models.

The Gist

The Big Picture: A Fortress with a Secret Door

Imagine Glioblastoma (a very aggressive brain cancer) not just as a lump of bad cells, but as a hostile fortress built inside the brain. This fortress has a special trick: it builds a "force field" that pushes away the body's immune system (the "police" or "soldiers" meant to destroy it).

For a long time, doctors tried to break this force field using "checkpoint inhibitors" (drugs like anti-PD1). Think of these drugs as trying to wake up the sleeping police officers. But in brain cancer, these drugs often fail. The police just won't wake up or get into the fortress.

This paper asks: Why is the police force so ineffective against this specific brain cancer?

The answer lies in a protein called EGFL7.

---

The Villain: EGFL7 (The "Smoke Machine")

The researchers discovered that the cancer cells and the blood vessels around them pump out a lot of a protein called EGFL7.

• The Analogy: Imagine EGFL7 is a thick, smoky fog that the cancer releases into the battlefield.
• What it does: This fog confuses the immune system. It doesn't just hide the cancer; it actively tricks the immune cells into giving up.
  • T-Cells (The Attack Dogs): The fog makes them tired, exhausted, and lazy. Instead of attacking, they just sit around doing nothing (a state scientists call "exhaustion").
  • Macrophages (The Janitors): Normally, some of these cells are "Good Janitors" (M1) that eat the trash and fight the cancer. The fog turns them into "Bad Janitors" (M2) who actually help the cancer build walls and hide better.

The Result: The cancer grows faster, and the patient's survival time drops.

The Secret Weapon: The "Handshake" (EGFL7 and ITGB2)

The researchers wanted to know how EGFL7 tricks the immune cells. They looked at the molecular level and found a specific handshake.

• The Mechanism: The immune cells have a specific receptor on their surface called ITGB2 (think of it as a keyhole).
• The Trick: EGFL7 acts like a fake key or a glue. It sticks to the ITGB2 keyhole.
• The Consequence: Once EGFL7 is stuck there, it jams the lock. The immune cell can no longer receive the "Go fight!" signal. It can't move toward the cancer, and it can't wake up. It's like trying to drive a car with the steering wheel glued to the dashboard.

The Experiments: Proving the Theory

The team tested this in mice with brain tumors using three main strategies:

1. Adding the Fog (Gain-of-Function): They forced cancer cells to make more EGFL7.
   • Result: The mice died faster, and the tumors were huge. The immune system was completely shut down.
2. Removing the Fog (Loss-of-Function): They used mice that couldn't make EGFL7 at all.
   • Result: The mice lived much longer. The immune system stayed awake, the "Good Janitors" fought the cancer, and the tumors were smaller.
3. Blocking the Keyhole (ITGB2 Knockout): They removed the "keyhole" (ITGB2) from the immune cells so EGFL7 couldn't stick.
   • Result: Even if the cancer tried to release the fog, it had nowhere to stick. The immune system worked again, and the mice survived longer.

The Solution: A Two-Pronged Attack

The most exciting part of the paper is the potential cure.

• The Problem: Using just the "wake-up" drug (anti-PD1) didn't work well because the fog (EGFL7) was too strong.
• The Fix: The researchers tried a combination therapy:
  1. Drug A (Anti-EGFL7): A drug that wipes out the "smoke/fog."
  2. Drug B (Anti-PD1): The standard drug that tries to wake up the police.

The Outcome: When they used both drugs together, it was a game-changer. By removing the fog first, the "wake-up" drug could finally work. The immune system attacked the tumor aggressively, and the mice survived significantly longer than with either drug alone.

Summary in Plain English

1. Brain cancer creates a protein (EGFL7) that acts like a smoke screen.
2. This smoke screen glues shut the receptors on immune cells, making them tired and useless.
3. If you remove the smoke (block EGFL7) or unstick the glue (block the receptor), the immune system wakes up and fights the cancer.
4. Combining a drug that removes the smoke with current immunotherapy drugs could finally make these treatments work for brain cancer patients, offering a new hope for a disease that is currently very hard to treat.

The Bottom Line: This study found a specific "lock" the cancer uses to disable our immune system. By picking that lock, we might finally be able to let our body's natural defenses do their job.

Technical Summary

1. Problem Statement

Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a dismal prognosis (median survival of 15–18 months) and inevitable recurrence. A major barrier to effective treatment is the immunosuppressive tumor microenvironment (GME), which facilitates immune evasion. While immune checkpoint inhibitors (e.g., anti-PD1) have revolutionized treatment for other solid tumors, they have shown limited efficacy in GBM. The molecular mechanisms driving this specific immunosuppressive landscape, particularly the role of tumor-intrinsic factors in shaping immune cell exhaustion and polarization, remain poorly understood. The authors investigate the role of Epidermal Growth Factor-like protein 7 (EGFL7), a secreted pro-angiogenic factor, in mediating this immune evasion.

2. Methodology

The study employed a multi-modal approach combining clinical data analysis, in vivo mouse models, in vitro assays, and advanced omics technologies:

• Clinical Data Analysis: Correlation of EGFL7 expression with patient survival and immune cell infiltration using the Chinese Glioma Genome Atlas (CGGA), The Cancer Genome Atlas (TCGA), and the Tumor Immune Estimation Resource (TIMER).
• Animal Models:
  • Gain-of-Function: Orthotopic implantation of GL261 and SB28 glioma cells ectopically expressing murine EGFL7 (mEGFL7) into wild-type C57BL/6J mice.
  • Loss-of-Function: Implantation of control glioma cells into constitutive EGFL7 knockout (EGFL7-/-) mice.
  • Immunodeficiency Control: Implantation of mEGFL7-expressing tumors into NSG (immunodeficient) mice to isolate immune-dependent effects.
  • Conditional Knockout: Generation of ITGB2^fl/fl;Scl-CreERT mice to induce hematopoietic stem cell (HSC)-specific deletion of Integrin β2 (ITGB2) via tamoxifen, allowing for the study of EGFL7-ITGB2 axis dependency on immune cells.
• Omics Profiling:
  • Single-cell RNA Sequencing (scRNA-seq): Analysis of CD45+ immune cells isolated from tumors to characterize T cell exhaustion and macrophage polarization states.
  • Spatial Transcriptomics (10x Visium): Mapping the spatial distribution of immune cells within the tumor core vs. tumor shell in EGFL7-deficient vs. wild-type contexts.
  • Proteomics (Mass Spectrometry): Immunoprecipitation of V5-tagged EGFL7 followed by LC-MS/MS to identify protein interactors.
• Mechanistic Assays:
  • Co-immunoprecipitation (Co-IP): Validating physical interactions between EGFL7 and integrin subunits (specifically ITGB2 and its α-subunits).
  • Flow Cytometry: Quantifying immune cell populations (PD1+ CD8+ T cells, M1 vs. M2 macrophages) in tumor tissues and in vitro cultures.
  • Functional Assays: In vitro stimulation of T cells and bone marrow-derived macrophages (BMDMs) with recombinant EGFL7 to assess direct effects on activation and polarization.
• Therapeutic Intervention: Testing the efficacy of anti-EGFL7 antibodies alone and in combination with anti-PD1 checkpoint blockade in orthotopic glioma models.

3. Key Contributions

• Identification of EGFL7 as an Immune Evasion Driver: The study establishes EGFL7 not just as an angiogenic factor, but as a critical regulator of the GME that actively suppresses anti-tumor immunity.
• Discovery of the EGFL7-ITGB2 Axis: The authors identified Integrin β2 (ITGB2, CD18) as the primary receptor for EGFL7 on immune cells. They demonstrated that EGFL7 preferentially binds the ITGAL-ITGB2 heterodimer (LFA-1) on T cells and ITGAD-ITGB2 on macrophages.
• Mechanistic Insight: The paper elucidates how EGFL7 binding to ITGB2 directly induces T cell exhaustion and drives macrophage polarization from pro-inflammatory (M1) to pro-tumorigenic (M2) states.
• Therapeutic Strategy: The study proposes and validates a combinatorial therapeutic approach (Anti-EGFL7 + Anti-PD1) that overcomes the resistance of GBM to single-agent checkpoint inhibition.

4. Key Results

• Clinical Correlation: High EGFL7 expression correlates with high-grade glioma, poor patient survival, increased levels of exhausted T cells, and higher infiltration of M2-like macrophages in human GBM samples.
• In Vivo Phenotype:
  • Gain-of-Function: EGFL7 overexpression significantly reduced mouse survival and increased tumor volume. This effect was abolished in immunodeficient (NSG) mice, confirming the phenotype is immune-mediated.
  • Loss-of-Function: EGFL7 knockout mice exhibited prolonged survival and smaller tumors compared to controls.
• Immune Landscape Remodeling:
  • T Cells: EGFL7 promotes the accumulation of exhausted CD8+ T cells (PD1+ Lag3+ Gzma^low) and reduces effector T cells (Gzma+ Gzmb+).
  • Macrophages: EGFL7 drives a shift from M1-like (CD80+ iNOS+) to M2-like (Arg1+ CD206+) macrophages. Spatial transcriptomics revealed that EGFL7 restricts M1 and effector T cell infiltration into the tumor core while enriching M2-like macrophages there.
• Molecular Mechanism:
  • Mass spectrometry identified ITGB2 as a top EGFL7 interactor.
  • Co-IP confirmed EGFL7 binds ITGB2, specifically the ITGAL-ITGB2 (LFA-1) complex on T cells.
  • Rescue Experiment: In mice with HSC-specific ITGB2 deletion, the pro-tumorigenic effects of EGFL7 (T cell exhaustion and M2 polarization) were rescued, proving the effect is ITGB2-dependent and immune-cell intrinsic.
  • In vitro data confirmed recombinant EGFL7 directly inhibits T cell activation and promotes M2 macrophage polarization.
• Therapeutic Efficacy:
  • Anti-PD1 monotherapy failed to improve survival in the glioma model.
  • Combination Therapy: The combination of anti-EGFL7 and anti-PD1 significantly prolonged survival (median 40 days vs. 33 days for control) and reduced tumor volume. This regimen resulted in a four-fold increase in functional CD8+ effector T cells (Gzmb+ IFNγ+) compared to controls.

5. Significance

This study provides a novel mechanistic framework for understanding glioblastoma immune evasion. It identifies EGFL7 as a "double-edged sword" that promotes angiogenesis while simultaneously suppressing the immune response via the ITGB2 receptor.

• Scientific Impact: It resolves the mystery of why anti-PD1 therapies fail in GBM by identifying a tumor-intrinsic factor (EGFL7) that creates a barrier to T cell infiltration and function.
• Clinical Relevance: The findings suggest that targeting the EGFL7-ITGB2 axis could be a viable strategy to "re-sensitize" GBM to immunotherapy. The successful demonstration that anti-EGFL7 enhances anti-PD1 efficacy offers a concrete, translational path forward for clinical trials, potentially improving outcomes for patients who currently have no effective immunotherapeutic options.
• Future Directions: The study highlights the potential of using anti-EGFL7 antibodies (e.g., parsatuzumab) as an add-on therapy to checkpoint inhibitors, moving beyond the current limitations of single-agent immunotherapy in brain tumors.